Thursday, December 3, 2020
close [x]
to:

Вакцина от COVID-19, разработанная Pfizer совместно с BioNTech (143)

2... from 2

lightboxes

You have to log in to have access to lightboxes

 

EN_01453364_0046
EN_01453364_0046
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0047
EN_01453364_0047
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0048
EN_01453364_0048
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0049
EN_01453364_0049
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0050
EN_01453364_0050
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0051
EN_01453364_0051
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0052
EN_01453364_0052
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0053
EN_01453364_0053
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0054
EN_01453364_0054
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0055
EN_01453364_0055
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0056
EN_01453364_0056
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0057
EN_01453364_0057
MAINZ, GERMANY - NOVEMBER 12: A view of BioNTech Headquarters in Mainz, Germany on November 12, 2020. The pharmaceutical company BioNTech, which Dr. Ugur Sahin and his wife, Dr. Ozlem Tureci, founded in 2008, managed to develop an experimental vaccine together with its American partner Pfizer which was found to be more than 90% effective in preventing COVID-19. Abdulhamid Hosbas / Anadolu Agency/ABACAPRESS.COM
EN_01453364_0082
EN_01453364_0082
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0083
EN_01453364_0083
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0084
EN_01453364_0084
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0085
EN_01453364_0085
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0086
EN_01453364_0086
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0087
EN_01453364_0087
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0088
EN_01453364_0088
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0089
EN_01453364_0089
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0090
EN_01453364_0090
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0091
EN_01453364_0091
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0092
EN_01453364_0092
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0093
EN_01453364_0093
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0094
EN_01453364_0094
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0095
EN_01453364_0095
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453364_0096
EN_01453364_0096
Illustration PFIZER in Paris on november 12, 2020 - The CEO of Pfizer sold $ 5.6 million in shares on the day of the announcement of the latest encouraging results from his vaccine, "90% effective" against Covid-19. Photo by ELIOT BLONDET/ABACAPRESS.COM
EN_01453235_0631
EN_01453235_0631
A man entry at the building where Pfizer's office located in Thessaloniki on November 10, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Sakis MITROLIDIS / AFP)
EN_01453324_0732
EN_01453324_0732
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0733
EN_01453324_0733
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0734
EN_01453324_0734
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0735
EN_01453324_0735
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0736
EN_01453324_0736
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0737
EN_01453324_0737
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0738
EN_01453324_0738
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453324_0739
EN_01453324_0739
Pharmaceutical laboratory of Pfizer in Capelle aan den IJssel, The Netherlands on November 10, 2020. Covid-19 vaccine: American pharmaceutical company Pfizer Pfizer claims 90 percent effectiveness, EU wants to buy vaccine. The European Union is about to close the sale of hundreds of millions of doses of the corona vaccine from the pharmaceutical company Pfizer / BioNTech. Preliminary research results showing that the vaccine is 90 percent effective in preventing infection. Photo by Robin Utrecht/ABACAPRESS.COM
Netherlands and Germany Out
EN_01453364_0001
EN_01453364_0001
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. - Themenbild,Symbolfoto:Corona Impfstoff. Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt Eine Hand in Gummihandschuhe gehuellt haelt eine Einwegspritze mit Impfstoff zur Injektion mit einer Kanuele. BIONTECH Biotechnologie Unternehmen.
Themenbild,Symbolfoto
EN_01453364_0002
EN_01453364_0002
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. - Themenbild,Symbolfoto:Corona Impfstoff. Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt Eine Hand in Gummihandschuhe gehuellt haelt eine Einwegspritze mit Impfstoff zur Injektion mit einer Kanuele. BIONTECH Biotechnologie Unternehmen.
Themenbild,Symbolfoto
EN_01453364_0003
EN_01453364_0003
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. - Themenbild,Symbolfoto:Corona Impfstoff. Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt. Einwegspritze mit Impfstoff zur Injektion mit einer Kanuele. BIONTECH Biotechnologie Unternehmen.
Themenbild,Symbolfoto
EN_01453364_0004
EN_01453364_0004
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0005
EN_01453364_0005
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0006
EN_01453364_0006
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0007
EN_01453364_0007
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0008
EN_01453364_0008
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0009
EN_01453364_0009
November 10, 2020, Cambridge, Massachusetts, USA:Buildings occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0010
EN_01453364_0010
November 10, 2020, Cambridge, Massachusetts, USA: A logo sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0011
EN_01453364_0011
November 10, 2020, Cambridge, Massachusetts, USA: A logo sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0012
EN_01453364_0012
November 10, 2020, Cambridge, Massachusetts, USA: A logo sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0013
EN_01453364_0013
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0014
EN_01453364_0014
November 10, 2020, Cambridge, Massachusetts, USA: Sign outside of a facility occupied by Pfizer laboratory on Port Street in Cambridge. Pfizer Inc, an American multinational pharmaceutical corporation announced early data shows its coronavirus vaccine is more than 90% effective on Monday November 9, 2020. (Photo by Keiko Hiromi/AFLO)
MINIMUM PRICE 5 USD
EN_01453364_0097
EN_01453364_0097
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0098
EN_01453364_0098
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0099
EN_01453364_0099
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0100
EN_01453364_0100
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0101
EN_01453364_0101
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0102
EN_01453364_0102
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0103
EN_01453364_0103
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0104
EN_01453364_0104
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453364_0105
EN_01453364_0105
Puurs , 10/11/2020 Illustration picture shows Pfizer Logo and batmenaZos. Pfizer Laboratories Deploy Vaccine To Fight Covid-19 90% Effective Pix : Credit : Sierakowski Frederic / Isopix
EN_01453083_0995
EN_01453083_0995
A stock ticker with Pfizer stock information is shown at the New York Stock Exchange, Monday, Nov. 9, 2020. World markets rocketed higher after Pfizer said early data show its coronavirus vaccine is effective. That added to investor relief that results from the U.S. presidential election were finally decided, with Joe Biden declared the president-elect. (AP Photo/Mark Lennihan)
EN_01453083_1125
EN_01453083_1125
Pedestrians pass by the Pfizer world headquarters, Monday, Nov. 9, 2020, in New York. Pfizer said Monday that an early peek at the data on its coronavirus vaccine suggests the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration. (AP Photo/ Ted Shaffrey)
EN_01453083_1270
EN_01453083_1270
A pedestrian walk past Pfizer world headquarters, Monday Nov. 9, 2020, in New York. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1278
EN_01453083_1278
Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews), APTOPIX
EN_01453083_1281
EN_01453083_1281
Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1282
EN_01453083_1282
An ad for COVID-19 testing reflects on glass at a bus stop, as pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1283
EN_01453083_1283
Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1284
EN_01453083_1284
A bus stop ad for COVID-19 testing is shown outside Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1285
EN_01453083_1285
An ad for COVID-19 testing reflects on glass at a bus stop, as pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (AP Photo/Bebeto Matthews)
EN_01453083_1302
EN_01453083_1302
A general view of Pfizer Manufacturing Belgium in Puurs, Belgium, Monday, Nov. 9, 2020. Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration in the United States. (AP Photo/Virginia Mayo)
EN_01453083_1303
EN_01453083_1303
A general view of Pfizer Manufacturing Belgium in Puurs, Belgium, Monday, Nov. 9, 2020. Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration in the United States. (AP Photo/Virginia Mayo)
EN_01453083_1307
EN_01453083_1307
A general view of Pfizer Manufacturing Belgium in Puurs, Belgium, Monday, Nov. 9, 2020. Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration in the United States. (AP Photo/Virginia Mayo)
EN_01453083_1308
EN_01453083_1308
A general view of Pfizer Manufacturing Belgium in Puurs, Belgium, Monday, Nov. 9, 2020. Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration in the United States. (AP Photo/Virginia Mayo)
EN_01453083_1309
EN_01453083_1309
A general view of Pfizer Manufacturing Belgium in Puurs, Belgium, Monday, Nov. 9, 2020. Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration in the United States. (AP Photo/Virginia Mayo)
EN_01453083_1349
EN_01453083_1349
A sign with the Pfizer logo stands outside the corporate headquarters of Pfizer Canada in Montreal, on Monday, Nov. 9, 2020. On Monday, the company says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (Ryan Remiorz/The Canadian Press via AP)
MANDATORY CREDIT
EN_01453083_1352
EN_01453083_1352
A sign with the Pfizer logo stands outside the corporate headquarters of Pfizer Canada in Montreal, on Monday, Nov. 9, 2020. On Monday, the company says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (Ryan Remiorz/The Canadian Press via AP)
MANDATORY CREDIT
EN_01453083_1378
EN_01453083_1378
A sign with the Pfizer logo stands outside the corporate headquarters of Pfizer Canada in Montreal, on Monday, Nov. 9, 2020. On Monday, the company said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, but it doesn't mean a vaccine is imminent. (Ryan Remiorz/The Canadian Press via AP)
MANDATORY CREDIT
EN_01453364_0058
EN_01453364_0058
A man wearing a mask walks past a Pfizer sign outside their headquarters in New York City. Pharmaceutical company Pfizer announced positive early results on its COVID-19 vaccine trial and has proven to be 90% effective in preventing infection of the virus. (Photo by John Nacion / SOPA Images/Sipa USA)
*** World Rights ***
EN_01453364_0059
EN_01453364_0059
A woman walks past a Pfizer sign outside their headquarters in New York City. Pharmaceutical company Pfizer announced positive early results on its COVID-19 vaccine trial and has proven to be 90% effective in preventing infection of the virus. (Photo by John Nacion / SOPA Images/Sipa USA)
*** World Rights ***
EN_01453364_0060
EN_01453364_0060
A woman wearing a mask walks past a Pfizer sign outside their headquarters in New York City. Pharmaceutical company Pfizer announced positive early results on its COVID-19 vaccine trial and has proven to be 90% effective in preventing infection of the virus. (Photo by John Nacion / SOPA Images/Sipa USA)
*** World Rights ***
EN_01453364_0061
EN_01453364_0061
A Pfizer logo seen outside their headquarters in New York City. Pharmaceutical company Pfizer announced positive early results on its COVID-19 vaccine trial and has proven to be 90% effective in preventing infection of the virus. (Photo by John Nacion / SOPA Images/Sipa USA)
*** World Rights ***
EN_01453364_0062
EN_01453364_0062
A brass Pfizer logo is seen on at the entrance of the Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0063
EN_01453364_0063
A brass Pfizer logo is seen on at the entrance of the Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0064
EN_01453364_0064
People walk past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0065
EN_01453364_0065
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0066
EN_01453364_0066
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0067
EN_01453364_0067
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0068
EN_01453364_0068
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0069
EN_01453364_0069
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0070
EN_01453364_0070
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0071
EN_01453364_0071
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0072
EN_01453364_0072
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0073
EN_01453364_0073
People walk past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0074
EN_01453364_0074
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0075
EN_01453364_0075
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0076
EN_01453364_0076
People walk past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0077
EN_01453364_0077
A logo flag flies outside the Pfizer World Headquarters as the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0078
EN_01453364_0078
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0079
EN_01453364_0079
A man walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0080
EN_01453364_0080
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453364_0081
EN_01453364_0081
A woman walks past Pfizer World Headquarters after the drug maker announced that early tests on its experimental COVID-19 vaccine was 90% effective, and could be available by year???s end, New York, NY, November 9, 2020. As the United States set a record-breaking wave of coronavirus cases, the Dow Jones soared in early trading on the news of the vaccine???s efficacy, though it was reported that only about 50 million dose would be available at first and be distributed to health care workers and those at greater risk of contracting the coronavirus. (Anthony Behar/Sipa USA)
*** World Rights ***
EN_01453085_1344
EN_01453085_1344
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1345
EN_01453085_1345
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1346
EN_01453085_1346
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1347
EN_01453085_1347
People walk by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1348
EN_01453085_1348
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1400
EN_01453085_1400
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1403
EN_01453085_1403
Women wear facemasks as they walk by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1404
EN_01453085_1404
A general view of the Pfizer world headquarters in New York is seen on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1405
EN_01453085_1405
A general view of the Pfizer world headquarters in New York is seen on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1406
EN_01453085_1406
A general view of the Pfizer world headquarters in New York is seen on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1421
EN_01453085_1421
A woman wears a facemask as she walks by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453085_1422
EN_01453085_1422
People walk by the Pfizer world headquarters in New York on November 9, 2020. - Pfizer stock surged higher on November 9, 2020 prior to the opening of Wall Street trading after the company announced its vaccine is "90 percent effective" against Covid-19 infections. The news cheered markets worldwide, especially as coronavirus cases are spiking, forcing millions of people back into lockdown. (Photo by Kena Betancur / AFP)
EN_01453229_0012
EN_01453229_0012
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0013
EN_01453229_0013
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0014
EN_01453229_0014
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0015
EN_01453229_0015
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0016
EN_01453229_0016
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0017
EN_01453229_0017
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0018
EN_01453229_0018
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453229_0019
EN_01453229_0019
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453324_0619
EN_01453324_0619
The corporate headquarters of Pfizer Canada are seen Monday, November 9, 2020 in Montreal.Photo by Ryan Remiorz/Canadian Press/ABACAPRESS.COM
EN_01453324_0620
EN_01453324_0620
The corporate headquarters of Pfizer Canada are seen Monday, November 9, 2020 in Montreal.Photo by Ryan Remiorz/Canadian Press/ABACAPRESS.COM
EN_01453324_0621
EN_01453324_0621
The corporate headquarters of Pfizer Canada are seen Monday, November 9, 2020 in Montreal.Photo by Ryan Remiorz/Canadian Press/ABACAPRESS.COM
EN_01453324_1816
EN_01453324_1816
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453324_1817
EN_01453324_1817
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453324_1818
EN_01453324_1818
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453324_1819
EN_01453324_1819
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM
EN_01453324_1820
EN_01453324_1820
U.S pharmaceutical corporation Pfizer headquarters in New York City, NY on November 9, 2020. Pfizer coronavirus vaccine is more than 90% effective in preventing illness in final-stage clinical trials. Photo by Charles Guerin/ABACAPRESS.COM

top

2... from 2